image
Healthcare - Medical - Devices - NASDAQ - US
$ 0.895
-5.78 %
$ 48.9 M
Market Cap
-2.49
P/E
1. INTRINSIC VALUE

Cytosorbents Corporation engages in the research, development, and commercialization of medical devices with its blood purification technology platform incorporating a proprietary adsorbent and porous polymer technology. Its flagship product is CytoSorb, an extracorporeal cytokine filter for adjunctive therapy in the treatment of sepsis, adjunctive therapy in other critical care applications, prevention and treatment of perioperative complications of cardiopulmonary bypass surgery, and maintaining or enhancing the quality of solid organs harvested from donors for organ transplant. The company also develops VetResQ, a device for adjunctive therapy in the treatment of sepsis, pancreatitis, and other critical illnesses in animals; CytoSorb-XL, a device for adjunctive therapy in the treatment of sepsis and other critical illnesses; HemoDefend blood purification technology platform to reduce contaminants in the blood supply that can cause transfusion reactions or disease when administering blood and blood products to patients, as well as removal of anti-A and anti-B blood group antibodies from fresh whole blood and plasma; K+ontrol for treatment of severe hyperkalemia in patients with life-threatening conditions; and ContrastSorb for the removal of IV contrast in blood administered during CT imaging, an angiogram, or during a vascular interventional radiology procedure to reduce the risk of contrast-induced nephropathy.[ Read More ]

The intrinsic value of one CTSO stock under the base case scenario is HIDDEN Compared to the current market price of 0.895 USD, Cytosorbents Corporation is HIDDEN

2. FUNDAMENTAL ANALYSIS

Price Chart CTSO

image
FINANCIALS
36.3 M REVENUE
23.81%
-31.2 M OPERATING INCOME
0.99%
-28.5 M NET INCOME
13.12%
-21.7 M OPERATING CASH FLOW
23.30%
-936 K INVESTING CASH FLOW
85.50%
14.5 M FINANCING CASH FLOW
191.84%
8.61 B REVENUE
86945.09%
-4.4 B OPERATING INCOME
-135845.94%
-4.14 M NET INCOME
34.83%
-4.79 M OPERATING CASH FLOW
0.73%
-120 K INVESTING CASH FLOW
5.63%
9.83 M FINANCING CASH FLOW
1820.06%
Balance Sheet Decomposition Cytosorbents Corporation
image
Current Assets 25.7 M
Cash & Short-Term Investments 14.1 M
Receivables 6.06 M
Other Current Assets 5.51 M
Non-Current Assets 27.6 M
Long-Term Investments 0
PP&E 22.1 M
Other Non-Current Assets 5.44 M
Current Liabilities 14.5 M
Accounts Payable 3.8 M
Short-Term Debt 2.87 M
Other Current Liabilities 7.87 M
Non-Current Liabilities 15.4 M
Long-Term Debt 15.4 M
Other Non-Current Liabilities 0
EFFICIENCY
Earnings Waterfall Cytosorbents Corporation
image
Revenue 36.3 M
Cost Of Revenue 14 M
Gross Profit 22.4 M
Operating Expenses 48.3 M
Operating Income -31.2 M
Other Expenses -2.7 M
Net Income -28.5 M
RATIOS
61.60% GROSS MARGIN
61.60%
-85.86% OPERATING MARGIN
-85.86%
-78.43% NET MARGIN
-78.43%
-122.48% ROE
-122.48%
-53.52% ROA
-53.52%
-107.15% ROIC
-107.15%
FREE CASH FLOW ANALYSIS
Free Cash Flow Analysis Cytosorbents Corporation
image
Net Income -28.5 M
Depreciation & Amortization 2.03 M
Capital Expenditures -936 K
Stock-Based Compensation 3.7 M
Change in Working Capital 2.36 M
Others -132 K
Free Cash Flow -22.6 M
3. WALL STREET ANALYSTS ESTIMATES
Wall Street Analysts Price Targets Cytosorbents Corporation
image
CTSO has no price targets from Wall Street.
4. DIVIDEND ANALYSIS
0.00% DIVIDEND YIELD
0 USD DIVIDEND PER SHARE
5. COMPETITION
6. Ownership
Insider Ownership Cytosorbents Corporation
image
Sold
0-3 MONTHS
0 USD 0
3-6 MONTHS
0 USD 0
6-9 MONTHS
0 USD 0
9-12 MONTHS
0 USD 0
Bought
0 USD 0
0-3 MONTHS
0 USD 0
3-6 MONTHS
0 USD 0
6-9 MONTHS
466 K USD 8
9-12 MONTHS
Date Value Insider Amount Avg Price
11 months ago
Dec 13, 2023
Bought 30 K USD
Sobel Alan D.
Director
+ 22557
1.33 USD
11 months ago
Dec 13, 2023
Bought 15.8 K USD
Sobel Alan D.
Director
+ 7894
2 USD
11 months ago
Dec 13, 2023
Bought 30 K USD
Deliargyris Efthymios
Chief Medical Officer
+ 22557
1.33 USD
11 months ago
Dec 13, 2023
Bought 15.8 K USD
Deliargyris Efthymios
Chief Medical Officer
+ 7894
2 USD
11 months ago
Dec 13, 2023
Bought 25 K USD
Capponi Vincent
President & COO
+ 18797
1.33 USD
11 months ago
Dec 13, 2023
Bought 13.2 K USD
Capponi Vincent
President & COO
+ 6578
2 USD
11 months ago
Dec 13, 2023
Bought 50 K USD
BATOR MICHAEL G.
Director
+ 37594
1.33 USD
11 months ago
Dec 13, 2023
Bought 26.3 K USD
BATOR MICHAEL G.
Director
+ 13157
2 USD
11 months ago
Dec 13, 2023
Bought 10 K USD
Jones Edward Raymond
Director
+ 7519
1.33 USD
11 months ago
Dec 13, 2023
Bought 5.26 K USD
Jones Edward Raymond
Director
+ 2631
2 USD
11 months ago
Dec 13, 2023
Bought 50 K USD
BLOCH KATHLEEN P.
Chief Financial Officer
+ 37594
1.33 USD
11 months ago
Dec 13, 2023
Bought 26.3 K USD
BLOCH KATHLEEN P.
Chief Financial Officer
+ 13157
2 USD
11 months ago
Dec 13, 2023
Bought 10 K USD
Kim Jiny
Director
+ 7519
1.33 USD
11 months ago
Dec 13, 2023
Bought 5.26 K USD
Kim Jiny
Director
+ 2631
2 USD
11 months ago
Dec 13, 2023
Bought 100 K USD
Chan Phillip P.
Chief Executive Officer
+ 75188
1.33 USD
11 months ago
Dec 13, 2023
Bought 52.6 K USD
Chan Phillip P.
Chief Executive Officer
+ 26315
2 USD
1 year ago
Aug 07, 2023
Bought 3.15 K USD
BATOR MICHAEL G.
Director
+ 1000
3.15 USD
1 year ago
Aug 07, 2023
Bought 3.2 K USD
BATOR MICHAEL G.
Director
+ 1000
3.2 USD
1 year ago
Aug 04, 2023
Bought 3.23 K USD
BATOR MICHAEL G.
Director
+ 1000
3.23 USD
1 year ago
May 25, 2023
Bought 3.13 K USD
BLOCH KATHLEEN P.
Interim CFO
+ 1100
2.8481 USD
1 year ago
May 25, 2023
Bought 3.12 K USD
BLOCH KATHLEEN P.
Interim CFO
+ 1100
2.8394 USD
1 year ago
May 25, 2023
Bought 3.13 K USD
BLOCH KATHLEEN P.
Interim CFO
+ 1100
2.8483 USD
1 year ago
May 10, 2023
Bought 9.51 K USD
BLOCH KATHLEEN P.
Interim CFO
+ 3000
3.1699 USD
1 year ago
May 10, 2023
Bought 6.25 K USD
BLOCH KATHLEEN P.
Interim CFO
+ 2000
3.125 USD
1 year ago
May 10, 2023
Bought 15.3 K USD
BLOCH KATHLEEN P.
Interim CFO
+ 5000
3.0596 USD
1 year ago
Dec 08, 2022
Bought 7.38 K USD
Chan Phillip P.
Chief Executive Officer
+ 5859
1.26 USD
1 year ago
Dec 07, 2022
Bought 12.4 K USD
Chan Phillip P.
Chief Executive Officer
+ 9850
1.26 USD
1 year ago
Dec 06, 2022
Bought 18.1 K USD
Chan Phillip P.
Chief Executive Officer
+ 14291
1.264 USD
2 years ago
Sep 08, 2022
Bought 59.5 K USD
Chan Phillip P.
Chief Executive Officer
+ 35000
1.7 USD
2 years ago
Aug 25, 2022
Bought 1.91 K USD
Kim Jiny
director:
+ 1000
1.91 USD
2 years ago
Jun 21, 2022
Bought 3.6 K USD
Capponi Vincent
President and COO
+ 2000
1.8 USD
2 years ago
Jun 16, 2022
Bought 6 K USD
Capponi Vincent
See Remarks
+ 3000
2 USD
2 years ago
Jun 16, 2022
Bought 4.11 K USD
Chan Phillip P.
Chief Executive Officer
+ 2221
1.85 USD
2 years ago
Jun 09, 2022
Bought 34.8 K USD
Chan Phillip P.
Chief Executive Officer
+ 16000
2.174 USD
2 years ago
Jun 06, 2022
Bought 16.5 K USD
BLOCH KATHLEEN P.
Chief Financial Officer
+ 8700
1.8999 USD
2 years ago
May 23, 2022
Bought 6.35 K USD
Capponi Vincent
President and COO
+ 3127
2.03 USD
2 years ago
May 23, 2022
Bought 605 USD
Capponi Vincent
President and COO
+ 299
2.025 USD
2 years ago
May 23, 2022
Bought 3.21 K USD
Capponi Vincent
President and COO
+ 1574
2.04 USD
2 years ago
May 18, 2022
Bought 2.21 K USD
BATOR MICHAEL G.
Director
+ 1000
2.21 USD
2 years ago
May 18, 2022
Bought 4.4 K USD
BATOR MICHAEL G.
director:
+ 2000
2.2 USD
2 years ago
May 18, 2022
Bought 4.4 K USD
BATOR MICHAEL G.
Director
+ 2000
2.2 USD
2 years ago
May 18, 2022
Bought 4.4 K USD
BATOR MICHAEL G.
Director
+ 2000
2.2 USD
2 years ago
May 18, 2022
Bought 4.36 K USD
BATOR MICHAEL G.
Director
+ 2000
2.18 USD
2 years ago
May 18, 2022
Bought 4.36 K USD
BATOR MICHAEL G.
Director
+ 2000
2.18 USD
2 years ago
May 16, 2022
Bought 3.75 K USD
Jones Edward Raymond
director:
+ 1676
2.2366 USD
2 years ago
May 11, 2022
Bought 17.8 K USD
Sobel Alan D.
director:
+ 8800
2.02 USD
2 years ago
May 11, 2022
Bought 2.4 K USD
Sobel Alan D.
Director
+ 1200
1.999 USD
2 years ago
May 06, 2022
Bought 9.8 K USD
Kraus Al
director:
+ 5000
1.959 USD
2 years ago
Dec 30, 2021
Bought 22.1 K USD
Chan Phillip P.
Chief Executive Officer
+ 5462
4.05 USD
2 years ago
Dec 29, 2021
Bought 38.2 K USD
Chan Phillip P.
Chief Executive Officer
+ 9438
4.05 USD
2 years ago
Dec 29, 2021
Bought 404 USD
Chan Phillip P.
Chief Executive Officer
+ 100
4.04 USD
2 years ago
Dec 10, 2021
Bought 26.2 K USD
Chan Phillip P.
Chief Executive Officer
+ 5000
5.25 USD
2 years ago
Nov 23, 2021
Bought 19.9 K USD
BLOCH KATHLEEN P.
Chief Financial Officer
+ 4000
4.98 USD
3 years ago
Aug 31, 2021
Sell 37.6 K USD
Kraus Al
Director
- 4000
9.3978 USD
4 years ago
Nov 10, 2020
Sell 64 K USD
Kraus Al
Director
- 8000
8 USD
4 years ago
Apr 27, 2020
Sell 100 K USD
Capponi Vincent
Chief Operating Officer
- 10000
10 USD
4 years ago
Mar 10, 2020
Sell 28.1 K USD
Capponi Vincent
Chief Operating Officer
- 4677
6 USD
4 years ago
Dec 10, 2019
Bought 11 K USD
BLOCH KATHLEEN P.
Chief Financial Officer
+ 3000
3.6765 USD
4 years ago
Dec 06, 2019
Bought 59.4 K USD
Chan Phillip P.
President and CEO
+ 16500
3.6 USD
4 years ago
Nov 26, 2019
Bought 4.27 K USD
BLOCH KATHLEEN P.
Chief Financial Officer
+ 1000
4.2702 USD
5 years ago
Aug 16, 2019
Bought 31.4 K USD
BLOCH KATHLEEN P.
Chief Financial Officer
+ 6500
4.83 USD
5 years ago
Aug 09, 2019
Bought 8.27 K USD
BLOCH KATHLEEN P.
Chief Financial Officer
+ 1500
5.5156 USD
5 years ago
May 10, 2019
Bought 19.5 K USD
BLOCH KATHLEEN P.
Chief Financial Officer
+ 3000
6.4921 USD
5 years ago
Dec 07, 2018
Sell 228 K USD
Chan Phillip P.
President and CEO
- 24337
9.3695 USD
6 years ago
Sep 05, 2018
Sell 8.91 K USD
Chan Phillip P.
President and CEO
- 600
14.85 USD
6 years ago
Sep 05, 2018
Sell 77 K USD
Chan Phillip P.
President and CEO
- 5187
14.85 USD
6 years ago
Sep 06, 2018
Sell 42.8 K USD
Chan Phillip P.
President and CEO
- 2900
14.75 USD
6 years ago
Sep 07, 2018
Sell 38.5 K USD
Chan Phillip P.
President and CEO
- 2731
14.11 USD
6 years ago
Aug 30, 2018
Sell 376 K USD
Kraus Al
Director
- 26000
14.4724 USD
6 years ago
Aug 29, 2018
Sell 280 K USD
Capponi Vincent
Chief Operating Officer
- 20000
14 USD
6 years ago
Aug 28, 2018
Sell 124 K USD
Capponi Vincent
Chief Operating Officer
- 9565
13 USD
6 years ago
Aug 28, 2018
Sell 135 K USD
BLOCH KATHLEEN P.
Chief Financial Officer
- 10000
13.5 USD
6 years ago
Aug 03, 2018
Sell 2.57 K USD
BLOCH KATHLEEN P.
Chief Financial Officer
- 200
12.85 USD
6 years ago
Aug 03, 2018
Sell 79 K USD
BLOCH KATHLEEN P.
Chief Financial Officer
- 6200
12.75 USD
6 years ago
Aug 03, 2018
Sell 43.7 K USD
BLOCH KATHLEEN P.
Chief Financial Officer
- 3600
12.151 USD
6 years ago
Aug 03, 2018
Sell 99.4 K USD
Capponi Vincent
Chief Operating Officer
- 7600
13.08 USD
6 years ago
Aug 02, 2018
Sell 36.9 K USD
Capponi Vincent
Chief Operating Officer
- 2835
13 USD
6 years ago
Jun 14, 2018
Sell 136 K USD
Capponi Vincent
Chief Operating Officer
- 11367
12 USD
6 years ago
Jun 15, 2018
Sell 104 K USD
Capponi Vincent
Chief Operating Officer
- 8633
12 USD
6 years ago
May 17, 2018
Sell 80 K USD
Capponi Vincent
Chief Operating Officer
- 8000
10 USD
6 years ago
May 17, 2018
Sell 200 K USD
Capponi Vincent
Chief Operating Officer
- 20000
10 USD
6 years ago
May 16, 2018
Sell 43.6 K USD
Capponi Vincent
Chief Operating Officer
- 4846
9 USD
6 years ago
May 15, 2018
Sell 36 K USD
Capponi Vincent
Chief Operating Officer
- 4000
9 USD
6 years ago
May 15, 2018
Sell 28.4 K USD
Capponi Vincent
Chief Operating Officer
- 3154
9 USD
6 years ago
May 16, 2018
Sell 112 K USD
BLOCH KATHLEEN P.
Chief Financial Officer
- 12400
9 USD
6 years ago
May 15, 2018
Sell 108 K USD
BLOCH KATHLEEN P.
Chief Financial Officer
- 12400
8.75 USD
6 years ago
May 14, 2018
Sell 85 K USD
BLOCH KATHLEEN P.
Chief Financial Officer
- 10000
8.5 USD
6 years ago
Apr 17, 2018
Sell 990 USD
BLOCH KATHLEEN P.
Chief Financial Officer
- 120
8.25 USD
6 years ago
Feb 21, 2018
Sell 80 K USD
BLOCH KATHLEEN P.
Chief Financial Officer
- 10000
8 USD
6 years ago
Mar 15, 2018
Sell 92.2 K USD
BLOCH KATHLEEN P.
Chief Financial Officer
- 11176
8.25 USD
6 years ago
Mar 13, 2018
Sell 9.11 K USD
BLOCH KATHLEEN P.
Chief Financial Officer
- 1104
8.25 USD
6 years ago
Jan 12, 2018
Sell 96.1 K USD
BLOCH KATHLEEN P.
Chief Financial Officer
- 12400
7.75 USD
6 years ago
Jan 08, 2018
Sell 71.5 K USD
BLOCH KATHLEEN P.
Chief Financial Officer
- 10000
7.15 USD
6 years ago
Jan 08, 2018
Sell 89.9 K USD
BLOCH KATHLEEN P.
Chief Financial Officer
- 12400
7.25 USD
6 years ago
Jan 08, 2018
Sell 75 K USD
BLOCH KATHLEEN P.
Chief Financial Officer
- 10000
7.5 USD
6 years ago
Nov 27, 2017
Sell 28 K USD
Capponi Vincent
Chief Operating Officer
- 4000
7 USD
7 years ago
Jun 09, 2017
Bought 10.1 K USD
Mortensen Eric R.
Chief Medical Officer
+ 2500
4.0398 USD
7 years ago
Jun 09, 2017
Bought 6.18 K USD
BATOR MICHAEL G.
Director
+ 1500
4.12 USD
7 years ago
Jun 08, 2017
Bought 10 K USD
Capponi Vincent
Chief Operating Officer
+ 2500
4 USD
7 years ago
Jun 08, 2017
Bought 14.8 K USD
Chan Phillip P.
President and CEO
+ 3700
4 USD
7 years ago
Jun 08, 2017
Bought 8 K USD
Jones Edward Raymond
Director
+ 2000
3.9995 USD
7 years ago
Jun 08, 2017
Bought 1.99 K USD
Jones Edward Raymond
Director
+ 500
3.975 USD
7 years ago
Jun 05, 2017
Bought 25.2 K USD
Chan Phillip P.
President and CEO
+ 6300
4 USD
7 years ago
May 15, 2017
Bought 4.34 K USD
BLOCH KATHLEEN P.
Chief Financial Officer
+ 1000
4.3406 USD
7 years ago
Dec 09, 2016
Bought 24.8 K USD
Chan Phillip P.
President and CEO
+ 4600
5.4 USD
7 years ago
Dec 06, 2016
Bought 4.83 K USD
BLOCH KATHLEEN P.
Chief Financial Officer
+ 1000
4.8292 USD
8 years ago
Aug 24, 2016
Bought 24.4 K USD
Chan Phillip P.
President and CEO
+ 5000
4.89 USD
8 years ago
Jun 07, 2016
Bought 14.6 K USD
BATOR MICHAEL G.
Director
+ 3000
4.88 USD
10 years ago
Oct 09, 2014
Sell 9.92 K USD
NJTC INVESTMENT FUND, LP
10 percent owner
- 41331
0.24 USD
10 years ago
Oct 10, 2014
Sell 1.99 K USD
NJTC INVESTMENT FUND, LP
10 percent owner
- 8300
0.24 USD
10 years ago
Oct 14, 2014
Sell 1.38 K USD
NJTC INVESTMENT FUND, LP
10 percent owner
- 5752
0.24 USD
10 years ago
Aug 26, 2014
Sell 240 K USD
NJTC INVESTMENT FUND, LP
10 percent owner
- 40000
6.01 USD
10 years ago
Aug 27, 2014
Sell 87.8 K USD
NJTC INVESTMENT FUND, LP
10 percent owner
- 14400
6.1 USD
10 years ago
Aug 28, 2014
Sell 50.6 K USD
NJTC INVESTMENT FUND, LP
10 percent owner
- 8576
5.9 USD
10 years ago
Sep 05, 2014
Sell 24 K USD
NJTC INVESTMENT FUND, LP
10 percent owner
- 4000
6 USD
10 years ago
Sep 11, 2014
Sell 6 K USD
NJTC INVESTMENT FUND, LP
10 percent owner
- 1000
6 USD
10 years ago
Sep 12, 2014
Sell 1.31 K USD
NJTC INVESTMENT FUND, LP
10 percent owner
- 218
6 USD
10 years ago
Sep 15, 2014
Sell 4.22 K USD
NJTC INVESTMENT FUND, LP
10 percent owner
- 704
6 USD
8 years ago
Dec 09, 2015
Bought 15 K USD
BLOCH KATHLEEN P.
Chief Financial Officer
+ 2125
7.05 USD
9 years ago
Oct 29, 2015
Sell 30 K USD
Capponi Vincent
Chief Operating Officer
- 4000
7.5 USD
9 years ago
Oct 15, 2015
Sell 42.1 K USD
Kraus Al
Director
- 6774
6.2182 USD
9 years ago
Oct 08, 2015
Sell 63.9 K USD
Kraus Al
Director
- 10000
6.3913 USD
9 years ago
Oct 01, 2015
Sell 62.6 K USD
Kraus Al
Director
- 10000
6.2591 USD
9 years ago
Sep 24, 2015
Sell 64.4 K USD
Kraus Al
Director
- 10000
6.4361 USD
9 years ago
Sep 17, 2015
Sell 66.4 K USD
Kraus Al
Director
- 10000
6.6373 USD
9 years ago
Sep 10, 2015
Sell 72.6 K USD
Kraus Al
Director
- 10000
7.26 USD
9 years ago
Sep 03, 2015
Sell 72.6 K USD
Kraus Al
Director
- 10000
7.2585 USD
9 years ago
Aug 27, 2015
Sell 63.9 K USD
Kraus Al
Director
- 10000
6.3937 USD
9 years ago
Aug 20, 2015
Sell 72.6 K USD
Kraus Al
Director
- 10000
7.2631 USD
9 years ago
Aug 13, 2015
Sell 62.6 K USD
Kraus Al
Director
- 10000
6.2593 USD
9 years ago
Aug 06, 2015
Sell 64.8 K USD
Kraus Al
Director
- 10000
6.4827 USD
9 years ago
Jul 30, 2015
Sell 63.4 K USD
Kraus Al
Director
- 10000
6.3397 USD
9 years ago
Jul 23, 2015
Sell 62.8 K USD
Kraus Al
Director
- 10000
6.2777 USD
9 years ago
Jul 16, 2015
Sell 63.3 K USD
Kraus Al
Director
- 10000
6.3303 USD
9 years ago
Jul 09, 2015
Sell 59.8 K USD
Kraus Al
Director
- 10000
5.9779 USD
9 years ago
Jul 02, 2015
Sell 62.9 K USD
Kraus Al
Director
- 10000
6.2852 USD
9 years ago
Jun 24, 2015
Sell 22.4 K USD
Kraus Al
Director
- 3205
7 USD
9 years ago
Jun 25, 2015
Sell 74.3 K USD
Kraus Al
Director
- 10000
7.4346 USD
9 years ago
Jun 18, 2015
Sell 57.8 K USD
Kraus Al
Director
- 10000
5.7782 USD
9 years ago
Jun 11, 2015
Sell 62.9 K USD
Kraus Al
Director
- 10000
6.2883 USD
9 years ago
Jun 04, 2015
Sell 63 K USD
Kraus Al
Director
- 10000
6.3 USD
9 years ago
May 28, 2015
Sell 63.2 K USD
Kraus Al
Director
- 10000
6.3247 USD
9 years ago
May 21, 2015
Sell 60.8 K USD
Kraus Al
Director
- 10000
6.0823 USD
9 years ago
May 14, 2015
Sell 60 K USD
Kraus Al
Director
- 10000
5.9996 USD
9 years ago
Apr 24, 2015
Sell 30 K USD
Capponi Vincent
Chief Operating Officer
- 4000
7.5 USD
10 years ago
Nov 17, 2014
Sell 11.3 K USD
Kraus Al
Director
- 50000
0.226 USD
10 years ago
Nov 10, 2014
Sell 11.2 K USD
Kraus Al
Director
- 50000
0.225 USD
10 years ago
Nov 03, 2014
Sell 11.7 K USD
Kraus Al
Director
- 50000
0.2338 USD
10 years ago
Oct 27, 2014
Sell 24.2 K USD
Kraus Al
Director
- 100000
0.2425 USD
10 years ago
Oct 20, 2014
Sell 24.1 K USD
Kraus Al
Director
- 100000
0.241 USD
10 years ago
Oct 14, 2014
Sell 34.5 K USD
Gunton James T.
director, 10 percent owner:
- 143787
0.24 USD
10 years ago
Oct 14, 2014
Sell 11.8 K USD
Kraus Al
Director
- 50000
0.2368 USD
10 years ago
Oct 09, 2014
Sell 248 K USD
Gunton James T.
director, 10 percent owner:
- 1033262
0.24 USD
10 years ago
Oct 10, 2014
Sell 49.8 K USD
Gunton James T.
director, 10 percent owner:
- 207500
0.24 USD
10 years ago
Oct 06, 2014
Sell 11.4 K USD
Kraus Al
Director
- 50000
0.2281 USD
10 years ago
Sep 29, 2014
Sell 11.3 K USD
Kraus Al
Director
- 50000
0.2255 USD
10 years ago
Sep 25, 2014
Sell 9.36 K USD
Kraus Al
Director
- 41500
0.2255 USD
10 years ago
Sep 22, 2014
Sell 1.92 K USD
Kraus Al
Director
- 8500
0.2259 USD
10 years ago
Sep 15, 2014
Sell 4.22 K USD
Gunton James T.
director, 10 percent owner:
- 17600
0.24 USD
10 years ago
Sep 15, 2014
Sell 11.4 K USD
Kraus Al
Director
- 50000
0.2286 USD
10 years ago
Sep 11, 2014
Sell 6 K USD
Gunton James T.
director, 10 percent owner:
- 25000
0.24 USD
10 years ago
Sep 12, 2014
Sell 1.31 K USD
Gunton James T.
director, 10 percent owner:
- 5450
0.24 USD
10 years ago
Sep 05, 2014
Sell 24 K USD
Gunton James T.
director, 10 percent owner:
- 100000
0.24 USD
10 years ago
Sep 08, 2014
Sell 11.4 K USD
Kraus Al
Director
- 50000
0.2286 USD
10 years ago
Sep 02, 2014
Sell 12.5 K USD
Kraus Al
Director
- 50000
0.2496 USD
10 years ago
Sep 02, 2014
Bought 14.7 K USD
BLOCH KATHLEEN P.
Chief Financial Officer
+ 65000
0.2265 USD
10 years ago
Aug 28, 2014
Sell 50.6 K USD
Gunton James T.
Director
- 214387
0.2359 USD
10 years ago
Aug 26, 2014
Sell 240 K USD
Gunton James T.
Director
- 1000000
0.2404 USD
10 years ago
Aug 27, 2014
Sell 87.9 K USD
Gunton James T.
Director
- 360000
0.2441 USD
7. News
CytoSorbents And Converge Biotech Announce Strategic Partnership to Expand Sepsis and Critical Care Treatment with CytoSorb in India PRINCETON, N.J. and HYDERABAD, India, Nov. 11, 2024 (GLOBE NEWSWIRE) -- CytoSorbents Corporation (NASDAQ: CTSO), a leader in the treatment of life-threatening conditions in the intensive care unit (ICU) and during cardiac surgery through blood purification, and Converge Biotech, a prominent healthcare company with a strong critical care and infectious disease focus in India, are pleased to announce a new strategic collaboration where the two companies seek to expand their combined market reach in the sepsis and critical care markets in India with a broad synergistic product portfolio. globenewswire.com - 6 days ago
Cytosorbents Corporation (CTSO) Q3 2024 Earnings Call Transcript Cytosorbents Corporation (NASDAQ:CTSO ) Q3 2024 Earnings Conference Call November 7, 2024 4:30 PM ET Company Participants Adanna Alexander - IR Phillip Chan - CEO & Director Peter Mariani - CFO Conference Call Participants Tom Kerr - Zacks Small-Cap Research Operator Thank you for standing by. My name is Catherine, and I will be your conference operator today. seekingalpha.com - 1 week ago
CytoSorbents Submits DrugSorb-ATR Marketing Application to U.S. FDA to Reduce the Severity of Bleeding in Heart Bypass Surgery Patients on the Blood Thinner Ticagrelor and Provides Business Update CytoSorbents files for FDA De Novo marketing approval of DrugSorb-ATR to reduce the severity of CABG-related bleeding due to the blood thinner ticagrelor globenewswire.com - 1 month ago
CytoSorbents to Present at the H.C. Wainwright 26ᵗʰ Annual Global Investment Conference PRINCETON, N.J., Aug. 27, 2024 (GLOBE NEWSWIRE) -- CytoSorbents Corporation (NASDAQ: CTSO), a leader in the treatment of life-threatening conditions in the intensive care unit and cardiac surgery using blood purification via its proprietary polymer adsorption technology, today announced that the Dr. Phillip Chan, Chief Executive Officer, and Peter J. Mariani, Chief Financial Officer will be attending and presenting at the H.C. Wainwright 26th Annual Global Investment Conference being held September 9-11, 2024 at the Lotte New York Palace Hotel in New York, NY. globenewswire.com - 2 months ago
CytoSorbents Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) PRINCETON, N.J., Aug. 16, 2024 (GLOBE NEWSWIRE) -- CytoSorbents Corporation (NASDAQ: CTSO), a leader in the treatment of life-threatening conditions in the intensive care unit and cardiac surgery using blood purification via its proprietary polymer adsorption technology, today announced that it granted inducement equity awards on August 14, 2024 (the “Grant Date”) to its newly-hired Chief Financial Officer, Peter J. Mariani. globenewswire.com - 3 months ago
Cytosorbents Corporation (CTSO) Q2 2024 Earnings Call Transcript Cytosorbents Corporation (NASDAQ:CTSO ) Q2 2024 Earnings Conference Call August 13, 2024 4:30 PM ET Company Participants Eric Ribner - IR Phillip Chan - CEO Kathleen Bloch - CFO Vincent Capponi - President & COO Makis Deliargyris - Chief Medical Officer Peter Mariani - CFO Conference Call Participants Michael Sarcone - Jefferies Yuan Zhi - B. Riley Securities Tom Kerr - Zacks Investment Research Sean Lee - H.C. seekingalpha.com - 3 months ago
CytoSorbents Reports Second Quarter 2024 Financial and Operational Results PRINCETON, N.J., Aug. 13, 2024 (GLOBE NEWSWIRE) -- CytoSorbents Corporation (NASDAQ: CTSO), a pioneer in critical care and cardiac surgery blood purification technologies, today reported unaudited financial and operating results for the quarter ended June 30, 2024. globenewswire.com - 3 months ago
CytoSorbents Appoints Peter J. Mariani Chief Financial Officer PRINCETON, N.J., Aug. 13, 2024 (GLOBE NEWSWIRE) -- CytoSorbents Corporation (NASDAQ: CTSO), a leader in the treatment of life-threatening conditions in the intensive care unit and cardiac surgery using blood purification via its proprietary polymer adsorption technology, announces the appointment of Peter J. globenewswire.com - 3 months ago
CytoSorbents to Report Second Quarter 2024 Operating and Financial Results PRINCETON, N.J., Aug. 07, 2024 (GLOBE NEWSWIRE) -- CytoSorbents Corporation (NASDAQ: CTSO), a leader in the treatment of life-threatening conditions in the intensive care unit and cardiac surgery using blood purification, will report second quarter 2024 operating and financial results after the market close on Tuesday, August 13, 2024. globenewswire.com - 3 months ago
CytoSorbents Announces Compliance with Nasdaq Minimum Bid Price Requirement PRINCETON, N.J., Aug. 01, 2024 (GLOBE NEWSWIRE) -- CytoSorbents Corporation (NASDAQ: CTSO), a leader in the treatment of deadly conditions in the intensive care unit and cardiac surgery using blood purification via its proprietary polymer adsorption technology, announces that it has regained compliance with the Nasdaq Stock Market's minimum bid price requirement of $1.00 per share. globenewswire.com - 3 months ago
CytoSorbents Unveils Newly Redesigned, Unified Company and Product Website PRINCETON, N.J., July 30, 2024 (GLOBE NEWSWIRE) -- CytoSorbents Corporation (NASDAQ: CTSO), a leader in the treatment of deadly conditions in the intensive care unit and cardiac surgery using blood purification via its proprietary polymer adsorption technology, is proud to announce the launch of its newly redesigned and consolidated website at www.cytosorbents.com. globenewswire.com - 3 months ago
CytoSorbents to Present at the Inaugural American Association of Physicians of Indian Origin (AAPI) World Health Congress CytoSorbents CEO Dr. Phillip Chan to highlight its innovative critical care and cardiac surgery blood purification therapy at AAPI Conference this weekend globenewswire.com - 4 months ago
8. Profile Summary

Cytosorbents Corporation CTSO

image
COUNTRY US
INDUSTRY Medical - Devices
MARKET CAP $ 48.9 M
Dividend Yield 0.00%
Description Cytosorbents Corporation engages in the research, development, and commercialization of medical devices with its blood purification technology platform incorporating a proprietary adsorbent and porous polymer technology. Its flagship product is CytoSorb, an extracorporeal cytokine filter for adjunctive therapy in the treatment of sepsis, adjunctive therapy in other critical care applications, prevention and treatment of perioperative complications of cardiopulmonary bypass surgery, and maintaining or enhancing the quality of solid organs harvested from donors for organ transplant. The company also develops VetResQ, a device for adjunctive therapy in the treatment of sepsis, pancreatitis, and other critical illnesses in animals; CytoSorb-XL, a device for adjunctive therapy in the treatment of sepsis and other critical illnesses; HemoDefend blood purification technology platform to reduce contaminants in the blood supply that can cause transfusion reactions or disease when administering blood and blood products to patients, as well as removal of anti-A and anti-B blood group antibodies from fresh whole blood and plasma; K+ontrol for treatment of severe hyperkalemia in patients with life-threatening conditions; and ContrastSorb for the removal of IV contrast in blood administered during CT imaging, an angiogram, or during a vascular interventional radiology procedure to reduce the risk of contrast-induced nephropathy. In addition, it is involved in the development of BetaSorb, a device for the prevention and treatment of health complications caused by the accumulation of metabolic toxins in patients with chronic renal failure; DrugSorb, a device to remove toxic chemicals from the blood; and DrugSorb-ATR, an antithrombotic removal system. The company was formerly known as MedaSorb Technologies Corporation and changed its name to Cytosorbents Corporation in May 2010. Cytosorbents Corporation was founded in 1997 and is headquartered in Princeton, New Jersey.
Contact 305 College Road East, Princeton, NJ, 08540 https://www.cytosorbents.com
IPO Date Aug. 8, 2006
Employees 186
Officers Dr. Efthymios N. Deliargyris FACC, FESC, FSCAI, M.D. Chief Medical Officer Mr. Vincent J. Capponi M.S. President & Chief Operating Officer Dr. Phillip P. Chan M.D., Ph.D. Chief Executive Officer & Director